- Home
- CELC vs MLCO Comparison
CELC vs MLCO Comparison
Compare CELC & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- MLCO
- Stock Information
- Founded
- CELC 2011
- MLCO 2004
- Country
- CELC United States
- MLCO Hong Kong
- Employees
- CELC N/A
- MLCO N/A
- Industry
- CELC Medical Specialities
- MLCO Hotels/Resorts
- Sector
- CELC Health Care
- MLCO Consumer Discretionary
- Exchange
- CELC Nasdaq
- MLCO Nasdaq
- Market Cap
- CELC 3.1B
- MLCO 3.2B
- IPO Year
- CELC 2017
- MLCO 2006
- Fundamental
- Price
- CELC $74.11
- MLCO $8.38
- Analyst Decision
- CELC Strong Buy
- MLCO Buy
- Analyst Count
- CELC 5
- MLCO 6
- Target Price
- CELC $69.40
- MLCO $9.78
- AVG Volume (30 Days)
- CELC 1.4M
- MLCO 2.6M
- Earning Date
- CELC 11-12-2025
- MLCO 11-06-2025
- Dividend Yield
- CELC N/A
- MLCO N/A
- EPS Growth
- CELC N/A
- MLCO N/A
- EPS
- CELC N/A
- MLCO 0.26
- Revenue
- CELC N/A
- MLCO $5,061,044,000.00
- Revenue This Year
- CELC N/A
- MLCO $12.67
- Revenue Next Year
- CELC N/A
- MLCO $3.25
- P/E Ratio
- CELC N/A
- MLCO $59.36
- Revenue Growth
- CELC N/A
- MLCO 11.46
- 52 Week Low
- CELC $7.58
- MLCO $4.55
- 52 Week High
- CELC $83.00
- MLCO $10.15
- Technical
- Relative Strength Index (RSI)
- CELC 64.02
- MLCO 50.82
- Support Level
- CELC $71.06
- MLCO $8.00
- Resistance Level
- CELC $79.97
- MLCO $8.41
- Average True Range (ATR)
- CELC 5.13
- MLCO 0.33
- MACD
- CELC 0.11
- MLCO 0.06
- Stochastic Oscillator
- CELC 53.43
- MLCO 66.30
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.